Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNBP - Nanobac Pharmaceuticals Inc. (Bulls Board) -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (84)	8/23/2007 6:28:00 PM
From: donpat	Respond to of 106

BG-Medicine HRP The High-Risk Plaque Initiative ("HRP Initiative") is a joint research and development effort to advance the understanding, recognition and management of high-risk plaque for the benefit of all stakeholders in the healthcare system. As the primary underlying cause of heart attacks, high-risk, or vulnerable plaque is the number one cause of death in the Western world. There are currently no methods of screening, diagnosis or treatment for high-risk plaque. The HRP Initiative will leverage recent advances in biology and technology to design and optimize a care-cycle for high-risk plaque, and promises to reduce morbidity, mortality and cost associated with cardiovascular disease. This Initiative, which comprises specific scientific studies and other activities, is being led by the world's foremost scientists in the fields of cardiology, pathology, and imaging, and is made possible through funding by leading pharmaceutical and medical technology entities. Goal of HRP Initiative To provide a roadmap for development and registration of screening, diagnostic and therapeutic interventions for high-risk plaque and promote their proper use to the benefit of patients, providers and payors. Specific Goals * Discover and validate screening blood biomarker * Optimize non-invasive imaging methods for characterization of high-risk patient, including: o Develop and validate novel digital analyses methods of images to characterize and classify patients * Establish the relationship between imaging and blood biomarkers and 3-year event rates * Develop regulatory framework for HRP-related products * Establish authoritative third-party source for HRP-related information * Explore development and validation of animal model for imaging modalities bg-medicine.com